GCG and obesity disorder: The focus of this mini-review is to present a brief overview of the synthetic short peptide tirzepatide as the first dual GLP-1 and GIP receptor agonist as a promising therapeutic agent for the treatment of either diabetes or obesity and to highlight its superiority to other similar agents.